Aadi Bioscience Inc reports results for the quarter ended in March - Earnings Summary

• Aadi Bioscience Inc AADI reported a quarterly adjusted loss of 68 cents​​ per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of -57 cents. The mean expectation of four analysts for the quarter was for a loss of 64 cents per share. Wall Street expected results to range from -71 cents to -62 cents per share.

• Revenue fell 8.8% to $5.35 million from a year ago; analysts expected $6.45 million.

• Aadi Bioscience Inc's reported EPS for the quarter was a loss of 68 cents​.

• The company reported a quarterly loss of $18.29 million.

• Aadi Bioscience Inc shares had fallen by 9.8% this quarter and gained 4.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Aadi Bioscience Inc is $14.00

This summary was machine generated from LSEG data May 8 at 02:12 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)